8-K: Telomir-1 Shows Promise in Aggressive Breast Cancer Models

Telomir Pharmaceuticals announced positive preclinical results for Telomir-1 in aggressive triple-negative breast cancer animal models, showing significant tumor growth and metastasis reduction.

Summary

• Telomir Pharmaceuticals reported results from a completed preclinical efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (TNBC).
• The study, conducted in collaboration with BioReperia, evaluated Telomir-1 administered alone and in combination with the chemotherapy agent paclitaxel.
• In two aggressive TNBC models, representing an estimated 40-60% of TNBC cases, Telomir-1 demonstrated statistically significant reductions in primary tumor growth.
• In one of these models, which was not responsive to paclitaxel, Telomir-1 was effective in reducing tumor growth both as a monotherapy and in combination with chemotherapy, and also demonstrated statistically significant reductions in cancer cell spread.
• In the other responsive model, Telomir-1 produced tumor growth inhibition comparable to paclitaxel as a monotherapy, and combination treatment resulted in greater tumor growth inhibition than either agent alone.
• In a third TNBC model, widely recognized as broadly treatment-resistant and representing an estimated 15-25% of TNBC cases, neither Telomir-1 nor paclitaxel produced statistically significant effects.
• The Company believes the differing responses reflect established biological differences among TNBC tumor types, particularly in how they regulate intracellular iron and copper and control epigenetically regulated gene activity.

Sentiment

Score: 8

Explanation: The preclinical results are significantly positive for a substantial portion of TNBC cases, demonstrating efficacy as monotherapy and in combination, and even in paclitaxel-resistant models. While not universally effective, the identified specificity is a strategic advantage for future development.

Positives

• Telomir-1 demonstrated statistically significant reductions in primary tumor growth in two aggressive triple-negative breast cancer (TNBC) models.
• In one aggressive TNBC model, Telomir-1 was effective as a monotherapy and in combination with chemotherapy, and significantly reduced cancer cell spread, even when paclitaxel was ineffective.
• In another aggressive TNBC model, Telomir-1 monotherapy showed comparable tumor growth inhibition to paclitaxel, and combination therapy resulted in greater tumor growth inhibition.
• The responsive TNBC models are estimated to account for approximately 40-60% of all TNBC cases.
• The findings provide important guidance for patient selection and future clinical trial design by helping to identify TNBC patient populations most likely to benefit from Telomir-1.

Negatives

• In a third TNBC model, widely recognized as broadly treatment-resistant and estimated to represent approximately 15-25% of TNBC cases, neither Telomir-1 nor paclitaxel produced statistically significant effects on primary tumor growth or cancer cell spread.

Risks

• Telomir-1's efficacy is specific to certain TNBC tumor types, implying it may not be effective for all TNBC patients.
• The study was preclinical, conducted in animal models, and results may not translate directly to human clinical trials.

Future Outlook

The Company is continuing IND-enabling activities and refining indication and patient population strategies informed by accumulated preclinical evidence, aiming to identify TNBC patient populations most likely to benefit from Telomir-1 based on underlying tumor biology.

Management Comments

• "The differing responses observed among the models outlines the specificity of this effect and may reflect established biological differences among TNBC tumor types in how they regulate intracellular iron and copper and in how they control epigenetically regulated gene activity."
• "The Company believes that these findings provide important guidance for patient selection and future clinical trial design by helping to identify TNBC patient populations most likely to benefit from Telomir-1 based on underlying tumor biology."

Industry Context

This announcement highlights ongoing efforts in the pharmaceutical industry to develop targeted therapies for difficult-to-treat cancers like triple-negative breast cancer, which lacks specific targeted treatments compared to other breast cancer subtypes. The use of preclinical models like zebrafish xenografts is a common early-stage drug development strategy to screen potential candidates before human trials.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive news regarding drug development progress could increase investor confidence and potentially share price.
• Patients: Potential for a new treatment option for a significant subset of aggressive triple-negative breast cancer.
• Employees: Continued progress in drug development supports the company's mission and job security.

Next Steps

• Continuing IND-enabling activities for Telomir-1.
• Refining indication and patient population strategies based on preclinical evidence.

Key Dates

Recommendation

The preclinical data for Telomir-1 in triple-negative breast cancer is highly encouraging, particularly its efficacy in aggressive models and in cases resistant to standard chemotherapy like paclitaxel. Identifying a specific patient population (40-60% of TNBC cases) where the drug shows significant benefit provides a clear path for clinical development and de-risks future trials. This positive early-stage data suggests strong potential for Telomir-1 to address a significant unmet medical need, making it a compelling investment opportunity for long-term growth.

Keywords

Telomir Pharmaceuticals, TELO, Telomir-1, Zn-Telomir, Triple-Negative Breast Cancer, TNBC, Preclinical Study, Zebrafish Model, Tumor Growth, Metastasis, Oncology, Drug Development, Biotechnology, Pharmaceuticals